iRhythm Q2 revenue $224M (+20% YoY), raises guidance; acquires VitalConnect for $287.5M

iRhythm Holdings, Inc.

Revenue $224.2M (+20.1% YoY); net loss $0.4M vs $14.2M loss; adjusted EBITDA $43.3M (19.3% margin).
FY2026 revenue guidance raised to $880-890M; adjusted EBITDA margin 13-14%.
Acquiring VitalConnect for ~$287.5M ($237.5M cash + $50M stock); expected close by end of 2026.
Settled Baxter patent litigation with $50M payment; cross-license and 6-year covenant not to sue.
FDA cleared third-gen algorithm; expected to cut clinician review time ~50% and save $100M over 5 years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.